They admit some don't respond to PPI meds.

[[e-mail] |]

1: Arzneimittelforschung. 2009;59(6):271-82.

Proton pump inhibitors--their pharmacological impact on the clinical
management of acid-related disorders.

Klotz U.

Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology,
Stuttgart,
Germany. ***@ikp-stuttgart.de

Acid secretion or intragastric pH play a very important role in the
pathophysiology of acid-related disorders such as peptic ulcer (PU),
gastrooesophageal reflux disease (GERD) or nonsteroidal anti-
inflammatory drug (NSAID)-induced gastrointestinal lesions. Proton
pump inhibitors (PPIs) represent the most potent/effective
antisecretory drugs for these indications. For the selection among the
various agents (omeprazole/esomeprazole (CAS 73590-58-6/119141-88-7),
pantoprazole (CAS 102625-70-7), lansoprazole (CAS103577-45-3),
rabeprazole (CAS 117976-83-3)) some features of their pharmacokinetic
(PK) and pharmacodynamic (PD) properties should be considered as
the clinical outcome depends on systemic drug exposure (PK) and
elevation of intragastric pH about certain threshold levels (PD). The
present review updates PK, PD and clinical data to provide some
guidance between the PPIs which differ somewhat in their metabolic
pattern and drug interaction potential. Based on 24-h intragastric pH
assessments the relative potencies of the PPIs compared to omeprazole
were in healthy volunteers (in GERD patients): 0.42 (0.59), 1.0 (0.8),
1.0 (1.0), 1.25 (1.25) and 2.0 (1.4) for pantoprazole, lansoprazole,
omeprazole, esomeprazole and rabeprazole, respectively. In general,
the clinical benefits of PPI are well documented but some patients
can be regarded as non-responders and
thus represent a challenge for future clinical research.


PMID: 19634508

[Yvan Hall]

www.superaffiliate7.com

Log on to Find out how you can make money by clicking my Web Site.
You will find good Affiiliates for health products, such as EDTA-Oral
Chelation,
Apricot kernels for cancer treament, Other affiliates are related to
Computers,
household products, Satellite TV (You may watch International Channel on
your Computer),
Download Commmercial Movies, Email, Free Horoscope.

Post by ***@gmail.com |
1: Arzneimittelforschung. 2009;59(6):271-82.
Proton pump inhibitors--their pharmacological impact on the clinical
management of acid-related disorders.
Klotz U.
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology,
Stuttgart,
Acid secretion or intragastric pH play a very important role in the
pathophysiology of acid-related disorders such as peptic ulcer (PU),
gastrooesophageal reflux disease (GERD) or nonsteroidal anti-
inflammatory drug (NSAID)-induced gastrointestinal lesions. Proton
pump inhibitors (PPIs) represent the most potent/effective
antisecretory drugs for these indications. For the selection among the
various agents (omeprazole/esomeprazole (CAS 73590-58-6/119141-88-7),
pantoprazole (CAS 102625-70-7), lansoprazole (CAS103577-45-3),
rabeprazole (CAS 117976-83-3)) some features of their pharmacokinetic
(PK) and pharmacodynamic (PD) properties should be considered as
the clinical outcome depends on systemic drug exposure (PK) and
elevation of intragastric pH about certain threshold levels (PD). The
present review updates PK, PD and clinical data to provide some
guidance between the PPIs which differ somewhat in their metabolic
pattern and drug interaction potential. Based on 24-h intragastric pH
assessments the relative potencies of the PPIs compared to omeprazole
were in healthy volunteers (in GERD patients): 0.42 (0.59), 1.0 (0.8),
1.0 (1.0), 1.25 (1.25) and 2.0 (1.4) for pantoprazole, lansoprazole,
omeprazole, esomeprazole and rabeprazole, respectively. In general,
the clinical benefits of PPI are well documented but some patients
can be regarded as non-responders and
thus represent a challenge for future clinical research.
PMID: 19634508

[Yvan Hall]

www.superaffiliate7.com

Log on to Find out how you can make money by clicking my Web Site.
You will find good Affiiliates for health products, such as EDTA-Oral
Chelation,
Apricot kernels for cancer treament, Other affiliates are related to
Computers,
household products, Satellite TV (You may watch International Channel on
your Computer),
Download Commmercial Movies, Email, Free Horoscope.

Post by ***@gmail.com |
1: Arzneimittelforschung. 2009;59(6):271-82.
Proton pump inhibitors--their pharmacological impact on the clinical
management of acid-related disorders.
Klotz U.
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology,
Stuttgart,
Acid secretion or intragastric pH play a very important role in the
pathophysiology of acid-related disorders such as peptic ulcer (PU),
gastrooesophageal reflux disease (GERD) or nonsteroidal anti-
inflammatory drug (NSAID)-induced gastrointestinal lesions. Proton
pump inhibitors (PPIs) represent the most potent/effective
antisecretory drugs for these indications. For the selection among the
various agents (omeprazole/esomeprazole (CAS 73590-58-6/119141-88-7),
pantoprazole (CAS 102625-70-7), lansoprazole (CAS103577-45-3),
rabeprazole (CAS 117976-83-3)) some features of their pharmacokinetic
(PK) and pharmacodynamic (PD) properties should be considered as
the clinical outcome depends on systemic drug exposure (PK) and
elevation of intragastric pH about certain threshold levels (PD). The
present review updates PK, PD and clinical data to provide some
guidance between the PPIs which differ somewhat in their metabolic
pattern and drug interaction potential. Based on 24-h intragastric pH
assessments the relative potencies of the PPIs compared to omeprazole
were in healthy volunteers (in GERD patients): 0.42 (0.59), 1.0 (0.8),
1.0 (1.0), 1.25 (1.25) and 2.0 (1.4) for pantoprazole, lansoprazole,
omeprazole, esomeprazole and rabeprazole, respectively. In general,
the clinical benefits of PPI are well documented but some patients
can be regarded as non-responders and
thus represent a challenge for future clinical research.
PMID: 19634508